The cardiometabolic burden of secondgeneration antipsychotics: a narrative synthesis of clinical evidence.

Saved in:

Bibliographic Details
Title:	The cardiometabolic burden of secondgeneration antipsychotics: a narrative synthesis of clinical evidence.
Alternate Title:	La carga cardiometabólica de los antipsicóticos de segunda generación: una síntesis narrativa de la evidencia clínica.
Authors:	Chávez-Castillo, Mervin¹ mervinch12@gmail.com, Niño, Carlos¹ Carninotorres@gmail.com, Vásquez, Laura¹ laurasvzc@gmail.com, Chirinos, Verónica¹ veronicachirinosmed@gmail.com, Duran, Pablo¹ pabloduran1998@gmail.com, Rivera-Porras, Diego² drivera23@cuc.edu.co, Solano-Jiménez, Donny-Sabrith³ donny.solano@unisimon.edu.co, Bermúdez, Valmore^4,5 Valmore.bermudez@unisimon.edu.co
Source:	Revista Latinoamericana de Hipertensión. 2025, Vol. 20 Issue 10, p648-661. 14p.
Subjects:	METABOLIC syndrome, CARDIOVASCULAR diseases, PEOPLE with diabetes, MENTAL health, MEDICAL research, ANTIPSYCHOTIC agents, CARDIOVASCULAR diseases risk factors, DRUG side effects
Abstract (English):	Second-generation antipsychotics (SGAs) are among the most prescribed psychotropic drugs worldwide. Nevertheless, their adverse effect profiles are notoriously broad and often pose clear challenges for tolerability, adherence, quality of life, and overall clinical success in everyday practice. Most alarmingly, a relationship has been described between SGAs and several metabolic disturbances, ultimately increasing the risk of metabolic syndrome, cardiovascular disease (CVD), diabetes, and other related conditions. However, characterizing this link is complex, as the impact of SGAs appears to be highly variable, not only based on clinical outcomes, but also in regards to a myriad of other patient-dependent factors, such as their age, sex, diagnosis, comorbidities and concurrent medication use. Appraisal of this interplay is pressing as CVD remains the leading global cause of morbidity and mortality. The outlook is further complicated by the intrinsically higher cardiometabolic risk entailed by severe mental illnesses such as schizophrenia--the model psychotic disorder--and other mental disorders where SGAs are often prescribed. Therefore, the objective of this narrative review is to revise the currently available clinical evidence on the relationships between SGAs and weight gain, hyperglycemia, dyslipidemia, hypertension, systemic inflammation, thrombotic risk and cardiovascular risk; in an effort to illuminate directions for clinical practice and future research. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	Los antipsicóticos de segunda generación (ASG) se encuentran entre los fármacos psicotrópicos más recetados a nivel mundial. Sin embargo, sus perfiles de efectos adversos son notoriamente amplios y a menudo plantean claros desafíos para la tolerabilidad, la adherencia, la calidad de vida y el éxito clínico general en la práctica diaria. Resulta aún más alarmante la relación descrita entre los ASG y diversas alteraciones metabólicas, que en última instancia aumentan el riesgo de síndrome metabólico, enfermedad cardiovascular (ECV), diabetes y otras afecciones relacionadas. Sin embargo, caracterizar esta relación es complejo, ya que el impacto de los ASG parece ser muy variable, no solo en función de los resultados clínicos, sino también en relación con una multitud de otros factores dependientes del paciente, como su edad, sexo, diagnóstico, comorbilidades y uso concomitante de medicamentos. La evaluación de esta interacción es urgente, ya que la ECV sigue siendo la principal causa mundial de morbilidad y mortalidad. El panorama se complica aún más por el riesgo cardiometabólico intrínsecamente mayor que conllevan las enfermedades mentales graves, como la esquizofrenia (el trastorno psicótico modelo) y otros trastornos mentales en los que se prescriben ASG con frecuencia. Por lo tanto, el objetivo de esta revisión narrativa es revisar la evidencia clínica disponible sobre la relación entre los ASG y el aumento de peso, la hiperglucemia, la dislipidemia, la hipertensión, la inflamación sistémica, el riesgo trombótico y el riesgo cardiovascular, con el fin de esclarecer las directrices para la práctica clínica y la investigación futura. [ABSTRACT FROM AUTHOR]
	Copyright of Revista Latinoamericana de Hipertensión is the property of Revista Latinoamericana de Hipertension and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	Second-generation antipsychotics (SGAs) are among the most prescribed psychotropic drugs worldwide. Nevertheless, their adverse effect profiles are notoriously broad and often pose clear challenges for tolerability, adherence, quality of life, and overall clinical success in everyday practice. Most alarmingly, a relationship has been described between SGAs and several metabolic disturbances, ultimately increasing the risk of metabolic syndrome, cardiovascular disease (CVD), diabetes, and other related conditions. However, characterizing this link is complex, as the impact of SGAs appears to be highly variable, not only based on clinical outcomes, but also in regards to a myriad of other patient-dependent factors, such as their age, sex, diagnosis, comorbidities and concurrent medication use. Appraisal of this interplay is pressing as CVD remains the leading global cause of morbidity and mortality. The outlook is further complicated by the intrinsically higher cardiometabolic risk entailed by severe mental illnesses such as schizophrenia--the model psychotic disorder--and other mental disorders where SGAs are often prescribed. Therefore, the objective of this narrative review is to revise the currently available clinical evidence on the relationships between SGAs and weight gain, hyperglycemia, dyslipidemia, hypertension, systemic inflammation, thrombotic risk and cardiovascular risk; in an effort to illuminate directions for clinical practice and future research. [ABSTRACT FROM AUTHOR]
ISSN:	18564550
DOI:	10.5281/zenodo.17622336